New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

Thankful for Biopharma Breakthroughs

Despite the constant need for social distancing, mask-wearing and the isolation and economic uncertainty that resulted from the Covid-19 outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.

2

AstraZeneca CEO expects to run new global trial of Covid-19 vaccine: Bloomberg

AstraZeneca is likely to run an additional global trial to assess the efficacy of the company’s Covid-19 vaccine using a lower dosage, the British drugmaker’s chief executive was quoted as saying amid questions over the results of a late-stage study.

3

Americans defy pandemic, political leaders to travel for Thanksgiving

Americans defied pleas from state and local officials to stay home for the Thanksgiving holiday in the face of the surging coronavirus pandemic, triggering fresh warnings from health officials with the release of vaccines still weeks away.

4

2020 HBA Annual Conference Recap

After capturing record-breaking attendance at its spring Illuminate event, the Healthcare Businesswomen’s Association (HBA) brought together – virtually – the biggest Annual Conference crowd in the group’s history with more than 1,600 attendees from 15 countries representing 250 healthcare and life science companies.

6

Global coronavirus cases surpass 60 million infections – Reuters tally

The global tally of confirmed coronavirus cases hit 60 million on Nov. 25, with the pace of new infections accelerating and the United States reporting record numbers of hospitalizations, according to a Reuters tally.

7

Q&A with Kate Cronin

Kate Cronin, Global CEO of Ogilvy Health, shares her views on a variety of healthcare industry topics in a Q&A with Med Ad News.

8

MediciNova’s Ibudilast Reduces Retinal Thinning in MS Trial Subjects

MediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.